formoterol (Foradil, Perforomist)
Jump to navigation
Jump to search
Introduction
Tradename: Foradil, Perforomist
Indications
- prevention of bronchospasm in patients with COPD or asthma
Contraindications
- NOT for treating symptoms of acute asthma (use albuterol)
- not for use in treating asthma without an inhaled glucocorticoid
Dosage
dry powder inhaler
Pharmacokinetics
- similar onset of action to albuterol, faster than salmeterol
Mechanism of action
- selective beta-2 agonist
Notes
Manufacturer: Novartis
More general terms
More specific terms
Component of
- budesonide/formoterol/glycopyrrolate (Breztri Aerosphere)
- formoterol/glycopyrrolate (Bevespi Aerosphere)
- formoterol/fumarate/mometasone
- budesonide/formoterol (Symbicort)
- formoterol/mometasone (Dulera)
References
- ↑ Prescriber's Letter 8(4):22 2001
- ↑ Prescriber's Letter 9(2):S1 2002
- ↑ 3.0 3.1 Prescriber's Letter 14(6): 2007 Long-acting Beta-2 Agonists for Nebulization Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230611&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ FDA advisory panel meeting Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety & Risk Management Advisory Committee, and the Pediatric Advisory Committee December 10 & 11, 2008 http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-00-index.htm